SEARCH:   Advanced

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Tsai, H. Search for Related Content PubMed PubMed Citation Articles by Tsai, H. Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion HM Tsai Division of Hematology, Montefiore Medical Center, Bronx, NY 10467, USA. von Willebrand factor (vWF) in the circulation is subjected to proteolysis. In a recent study, we reported that normal plasma contains a protease activity that cleaves vWF in a shear-dependent manner, causing a decrease in its multimer size while generating dimers of the 140-kD and the 176-kD fragments indistinguishable from those found in normal plasma. In this study, the plasma protease has been partially purified and characterized and the role of vWF conformation in its cleavage by the protease has been further investigated. Guanidine HCl caused unfolding of vWF in a concentration-dependent manner, resulting in a shift in its fluorescence emission maxima to longer wavelengths. A dramatic increase in its proteolytic susceptibility was seen at 1.1 to 1.2 mol/L guanidine HCl, a concentration causing only a 3- to 4-nm shift in vWF emission maxima. Although vWF molecules refolded as guanidine HCl was removed by dialysis, the refolding was accompanied only by a partial recovery of the proteolytic resistance. The plasma protease, partially purified by approximately 900 folds by Sephacryl S- 300 HR gel filtration, Matrex gel orange A dye affinity chromatography, and Q Sepharose anion exchange, had a molecular mass of approximately 200 kD and was inhibited by EDTA, EGTA, or 1,10-phenanthroline. The inhibition by EGTA or EDTA could be reversed by Ca2+ but not by mg2+. It was not inhibited by a panel of synthetic and natural protease inhibitors or adsorbed by gelatin-agarose, and it was present in plasmas deficient in proteins involved in coagulation and anticoagulation. The vWF fragments generated by the protease, as mapped by peptide-specific antibodies VP-1 and LJ-7745, were in distinguishable from the natural fragments but distinct from those produced by plasmin. High molecular weight endothelial vWF, after exposure to guanidine HCLI or high shear stress, was cleaved by the protease to smaller forms. These results support the model that endothelial secreted vWF is converted to multimers by a novel plasma metalloproteinase. Although native vWF exists in a conformation relatively resistant to cleavage, an alteration in the conformation by shear stress can lead to enhanced proteolytic susceptibility. This model may explain the decrease in vWF multimer sizes in various clinical conditions. Volume 87, Issue 10, pp. 4235-4244, 05/15/1996 Copyright © 1996 by The American Society of Hematology CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: N. A. Turner, L. Nolasco, Z. M. Ruggeri, and J. L. Moake Endothelial cell ADAMTS-13 and VWF: production, release, and VWF string cleavage Blood, December 3, 2009; 114(24): 5102 - 5111. [Abstract] [Full Text] [PDF] M. Akiyama, S. Takeda, K. Kokame, J. Takagi, and T. Miyata Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Willebrand factor PNAS, November 17, 2009; 106(46): 19274 - 19279. [Abstract] [Full Text] [PDF] A. N. Vomund and E. M. Majerus ADAMTS13 Bound to Endothelial Cells Exhibits Enhanced Cleavage of von Willebrand Factor J. Biol. Chem., November 6, 2009; 284(45): 30925 - 30932. [Abstract] [Full Text] [PDF] S. Zanardelli, A. C. K. Chion, E. Groot, P. J. Lenting, T. A. J. McKinnon, M. A. Laffan, M. Tseng, and D. A. Lane A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF Blood, September 24, 2009; 114(13): 2819 - 2828. [Abstract] [Full Text] [PDF] F. Yu, Y. Tan, and M.-H. Zhao Lupus nephritis combined with renal injury due to thrombotic thrombocytopaenic purpura-haemolytic uraemic syndrome Nephrol. Dial. Transplant., August 23, 2009; (2009) gfp421v1. [Abstract] [Full Text] [PDF] T. J. Raife, W. Cao, B. S. Atkinson, B. Bedell, R. R. Montgomery, S. R. Lentz, G. F. Johnson, and X. L. Zheng Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site Blood, August 20, 2009; 114(8): 1666 - 1674. [Abstract] [Full Text] [PDF] J. Christof, M. Gebhardt, and M. Rief Force Signaling in Biology Science, June 5, 2009; 324(5932): 1278 - 1280. [Abstract] [Full Text] [PDF] X. Zhang, K. Halvorsen, C.-Z. Zhang, W. P. Wong, and T. A. Springer Mechanoenzymatic Cleavage of the Ultralarge Vascular Protein von Willebrand Factor Science, June 5, 2009; 324(5932): 1330 - 1334. [Abstract] [Full Text] [PDF] Y. Abe, H. Wada, E. Yamada, M. Noda, M. Ikejiri, J. Nishioka, T. Kobayashi, T. Matsumoto, M. Masuya, S. Isaji, et al. The Effectiveness of Measuring for Fragmented Red Cells Using an Automated Hematology Analyzer in Patients With Thrombotic Microangiopathy Clinical and Applied Thrombosis/Hemostasis, June 1, 2009; 15(3): 257 - 262. [Abstract] [PDF] R. de Groot, A. Bardhan, N. Ramroop, D. A. Lane, and J. T. B. Crawley Essential role of the disintegrin-like domain in ADAMTS13 function Blood, May 28, 2009; 113(22): 5609 - 5616. [Abstract] [Full Text] [PDF] M. D. Gardner, C. K. N. K. Chion, R. de Groot, A. Shah, J. T. B. Crawley, and D. A. Lane A functional calcium-binding site in the metalloprotease domain of ADAMTS13 Blood, January 29, 2009; 113(5): 1149 - 1157. [Abstract] [Full Text] [PDF] I. Garagiola, C. Valsecchi, S. Lavoretano, H. Oren, M. Bohm, and F. Peyvandi Nonsense-mediated mRNA decay in the ADAMTS13 gene caused by a 29-nucleotide deletion Haematologica, November 1, 2008; 93(11): 1678 - 1685. [Abstract] [Full Text] [PDF] M. S. Buzza, J. M. Dyson, H. Choi, E. E. Gardiner, R. K. Andrews, D. Kaiserman, C. A. Mitchell, M. C. Berndt, J.-F. Dong, and P. I. Bird Antihemostatic Activity of Human Granzyme B Mediated by Cleavage of von Willebrand Factor J. Biol. Chem., August 15, 2008; 283(33): 22498 - 22504. [Abstract] [Full Text] [PDF] J. E. Sadler Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura Blood, July 1, 2008; 112(1): 11 - 18. [Abstract] [Full Text] [PDF] W. Cao, S. Krishnaswamy, R. M. Camire, P. J. Lenting, and X. L. Zheng Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13 PNAS, May 27, 2008; 105(21): 7416 - 7421. [Abstract] [Full Text] [PDF] M.-C. Chung, T. G. Popova, S. C. Jorgensen, L. Dong, V. Chandhoke, C. L. Bailey, and S. G. Popov Degradation of Circulating von Willebrand Factor and Its Regulator ADAMTS13 Implicates Secreted Bacillus anthracis Metalloproteases in Anthrax Consumptive Coagulopathy J. Biol. Chem., April 11, 2008; 283(15): 9531 - 9542. [Abstract] [Full Text] [PDF] B. Lammle, J. A. Kremer Hovinga, and J. N. George Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease Haematologica, February 1, 2008; 93(2): 172 - 177. [Full Text] [PDF] K. Shim, P. J. Anderson, E. A. Tuley, E. Wiswall, and J. Evan Sadler Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress Blood, January 15, 2008; 111(2): 651 - 657. [Abstract] [Full Text] [PDF] P. Zhang, W. Pan, A. H. Rux, B. S. Sachais, and X. L. Zheng The cooperative activity between the carboxyl-terminal TSP1 repeats and the CUB domains of ADAMTS13 is crucial for recognition of von Willebrand factor under flow Blood, September 15, 2007; 110(6): 1887 - 1894. [Abstract] [Full Text] [PDF] K. C. Desch and D. G. Motto Thrombotic Thrombocytopenic Purpura in Humans and Mice Arterioscler Thromb Vasc Biol, September 1, 2007; 27(9): 1901 - 1908. [Abstract] [Full Text] [PDF] P. M. Mannucci Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome: much progress and many remaining issues Haematologica, July 1, 2007; 92(7): 878 - 880. [Full Text] [PDF] J. A. Davies, P. W. Collins, L. S. Hathaway, and D. J. Bowen Effect of von Willebrand factor Y/C1584 on in vivo protein level and function and interaction with ABO blood group Blood, April 1, 2007; 109(7): 2840 - 2846. [Abstract] [Full Text] [PDF] A. K. Chauhan, J. Kisucka, C. B. Lamb, W. Bergmeier, and D. D. Wagner von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins Blood, March 15, 2007; 109(6): 2424 - 2429. [Abstract] [Full Text] [PDF] J. N. George Evaluation and Management of Patients With Thrombotic Thrombocytopenic Purpura J Intensive Care Med, March 1, 2007; 22(2): 82 - 91. [Abstract] [PDF] C. K. N. K. Chion, C. J. M. Doggen, J. T. B. Crawley, D. A. Lane, and F. R. Rosendaal ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men Blood, March 1, 2007; 109(5): 1998 - 2000. [Abstract] [Full Text] [PDF] J. A. Davies and D. J. Bowen An association between the L1565 variant of von Willebrand factor and susceptibility to proteolysis by ADAMTS13 Haematologica, February 1, 2007; 92(2): 240 - 243. [Abstract] [Full Text] [PDF] T. C. Nguyen, A. Liu, L. Liu, C. Ball, H. Choi, W. S. May, K. Aboulfatova, A. L. Bergeron, and J.-f. Dong Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis Haematologica, January 1, 2007; 92(1): 121 - 124. [Abstract] [Full Text] [PDF] P. M. Mannucci and F. Peyvandi TTP and ADAMTS13: When Is Testing Appropriate? Hematology, January 1, 2007; 2007(1): 121 - 126. [Abstract] [Full Text] [PDF] I. Singh, H. Shankaran, M. E. Beauharnois, Z. Xiao, P. Alexandridis, and S. Neelamegham Solution Structure of Human von Willebrand Factor Studied Using Small Angle Neutron Scattering J. Biol. Chem., December 15, 2006; 281(50): 38266 - 38275. [Abstract] [Full Text] [PDF] W. Gao, P. J. Anderson, E. M. Majerus, E. A. Tuley, and J. E. Sadler Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease PNAS, December 12, 2006; 103(50): 19099 - 19104. [Abstract] [Full Text] [PDF] J.-J. Wu, K. Fujikawa, B. A. McMullen, and D. W. Chung Characterization of a core binding site for ADAMTS-13 in the A2 domain of von Willebrand factor PNAS, December 5, 2006; 103(49): 18470 - 18474. [Abstract] [Full Text] [PDF] F. Banno, K. Kokame, T. Okuda, S. Honda, S. Miyata, H. Kato, Y. Tomiyama, and T. Miyata Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura Blood, April 15, 2006; 107(8): 3161 - 3166. [Abstract] [Full Text] [PDF] A. K. Chauhan, D. G. Motto, C. B. Lamb, W. Bergmeier, M. Dockal, B. Plaimauer, F. Scheiflinger, D. Ginsburg, and D. D. Wagner Systemic antithrombotic effects of ADAMTS13 J. Exp. Med., March 20, 2006; 203(3): 767 - 776. [Abstract] [Full Text] [PDF] W. A. Hassenpflug, U. Budde, T. Obser, D. Angerhaus, E. Drewke, S. Schneppenheim, and R. Schneppenheim Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis Blood, March 15, 2006; 107(6): 2339 - 2345. [Abstract] [Full Text] [PDF] R. Donadelli, J. N. Orje, C. Capoferri, G. Remuzzi, and Z. M. Ruggeri Size regulation of von Willebrand factor-mediated platelet thrombi by ADAMTS13 in flowing blood Blood, March 1, 2006; 107(5): 1943 - 1950. [Abstract] [Full Text] [PDF] S. Zanardelli, J. T. B. Crawley, C. K. N. C. K. Chion, J. K. Lam, R. J. S. Preston, and D. A. Lane ADAMTS13 Substrate Recognition of von Willebrand Factor A2 Domain J. Biol. Chem., January 20, 2006; 281(3): 1555 - 1563. [Abstract] [Full Text] [PDF] P. J. Anderson, K. Kokame, and J. E. Sadler Zinc and Calcium Ions Cooperatively Modulate ADAMTS13 Activity J. Biol. Chem., January 13, 2006; 281(2): 850 - 857. [Abstract] [Full Text] [PDF] B. Plaimauer, J. Fuhrmann, G. Mohr, W. Wernhart, K. Bruno, S. Ferrari, C. Konetschny, G. Antoine, M. Rieger, and F. Scheiflinger Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation Blood, January 1, 2006; 107(1): 118 - 125. [Abstract] [Full Text] [PDF] W. Zhou, L. Dong, D. Ginsburg, E. E. Bouhassira, and H.-M. Tsai Enzymatically Active ADAMTS13 Variants Are Not Inhibited by Anti-ADAMTS13 Autoantibodies: A NOVEL THERAPEUTIC STRATEGY? J. Biol. Chem., December 2, 2005; 280(48): 39934 - 39941. [Abstract] [Full Text] [PDF] J. Ai, P. Smith, S. Wang, P. Zhang, and X. L. Zheng The Proximal Carboxyl-terminal Domains of ADAMTS13 Determine Substrate Specificity and Are All Required for Cleavage of von Willebrand Factor J. Biol. Chem., August 19, 2005; 280(33): 29428 - 29434. [Abstract] [Full Text] [PDF] G. G. Levy, D. G. Motto, and D. Ginsburg ADAMTS13 turns 3 Blood, July 1, 2005; 106(1): 11 - 17. [Abstract] [Full Text] [PDF] E. M. Majerus, P. J. Anderson, and J. E. Sadler Binding of ADAMTS13 to von Willebrand Factor J. Biol. Chem., June 10, 2005; 280(23): 21773 - 21778. [Abstract] [Full Text] [PDF] J.-D. Studt, J. A. K. Hovinga, G. Antoine, M. Hermann, M. Rieger, F. Scheiflinger, and B. Lammle Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin Blood, January 15, 2005; 105(2): 542 - 544. [Abstract] [Full Text] [PDF] L. B. Ware, M. D. Eisner, B. T. Thompson, P. E. Parsons, and M. A. Matthay Significance of Von Willebrand Factor in Septic and Nonseptic Patients with Acute Lung Injury Am. J. Respir. Crit. Care Med., October 1, 2004; 170(7): 766 - 772. [Abstract] [Full Text] [PDF] K. Nishio, P. J. Anderson, X. L. Zheng, and J. E. Sadler Binding of platelet glycoprotein Ib{alpha} to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13 PNAS, July 20, 2004; 101(29): 10578 - 10583. [Abstract] [Full Text] [PDF] F. Banno, K. Kaminaka, K. Soejima, K. Kokame, and T. Miyata Identification of Strain-specific Variants of Mouse Adamts13 Gene Encoding von Willebrand Factor-cleaving Protease J. Biol. Chem., July 16, 2004; 279(29): 30896 - 30903. [Abstract] [Full Text] [PDF] C. Klaus, B. Plaimauer, J.-D. Studt, F. Dorner, B. Lammle, P. M. Mannucci, and F. Scheiflinger Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura Blood, June 15, 2004; 103(12): 4514 - 4519. [Abstract] [Full Text] [PDF] X. L. Zheng, R. M. Kaufman, L. T. Goodnough, and J. E. Sadler Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura Blood, June 1, 2004; 103(11): 4043 - 4049. [Abstract] [Full Text] [PDF] J.-D. Studt, J. A. K. Hovinga, R. Radonic, V. Gasparovic, D. Ivanovic, M. Merkler, U. Wirthmueller, C. Dahinden, M. Furlan, and B. Lammle Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twins Blood, June 1, 2004; 103(11): 4195 - 4197. [Abstract] [Full Text] [PDF] J. E. Pimanda, T. Ganderton, A. Maekawa, C. L. Yap, J. Lawler, G. Kershaw, C. N. Chesterman, and P. J. Hogg Role of Thrombospondin-1 in Control of von Willebrand Factor Multimer Size in Mice J. Biol. Chem., May 14, 2004; 279(20): 21439 - 21448. [Abstract] [Full Text] [PDF] A. Padilla, J. L. Moake, A. Bernardo, C. Ball, Y. Wang, M. Arya, L. Nolasco, N. Turner, M. C. Berndt, B. Anvari, et al. P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface Blood, March 15, 2004; 103(6): 2150 - 2156. [Abstract] [Full Text] [PDF] M. Matsumoto, K. Kokame, K. Soejima, M. Miura, S. Hayashi, Y. Fujii, A. Iwai, E. Ito, Y. Tsuji, M. Takeda-Shitaka, et al. Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome Blood, February 15, 2004; 103(4): 1305 - 1310. [Abstract] [Full Text] [PDF] K. Kokame, M. Matsumoto, Y. Fujimura, and T. Miyata VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13 Blood, January 15, 2004; 103(2): 607 - 612. [Abstract] [Full Text] [PDF] J. E. Pimanda, A. Maekawa, T. Wind, J. Paxton, C. N. Chesterman, and P. J. Hogg Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS13 Blood, January 15, 2004; 103(2): 627 - 629. [Abstract] [Full Text] [PDF] J. E. Sadler, J. L. Moake, T. Miyata, and J. N. George Recent Advances in Thrombotic Thrombocytopenic Purpura Hematology, January 1, 2004; 2004(1): 407 - 423. [Abstract] [Full Text] [PDF] E. M. Majerus, X. Zheng, E. A. Tuley, and J. E. Sadler Cleavage of the ADAMTS13 Propeptide Is Not Required for Protease Activity J. Biol. Chem., November 21, 2003; 278(47): 46643 - 46648. [Abstract] [Full Text] [PDF] K. Soejima, M. Matsumoto, K. Kokame, H. Yagi, H. Ishizashi, H. Maeda, C. Nozaki, T. Miyata, Y. Fujimura, and T. Nakagaki ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage Blood, November 1, 2003; 102(9): 3232 - 3237. [Abstract] [Full Text] [PDF] F. Scheiflinger, P. Knobl, B. Trattner, B. Plaimauer, G. Mohr, M. Dockal, F. Dorner, and M. Rieger Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura Blood, November 1, 2003; 102(9): 3241 - 3243. [Abstract] [Full Text] [PDF] J.-f. Dong, J. L. Moake, A. Bernardo, K. Fujikawa, C. Ball, L. Nolasco, J. A. Lopez, and M. A. Cruz ADAMTS-13 Metalloprotease Interacts with the Endothelial Cell-derived Ultra-large von Willebrand Factor J. Biol. Chem., August 8, 2003; 278(32): 29633 - 29639. [Abstract] [Full Text] [PDF] X. Zheng, K. Nishio, E. M. Majerus, and J. E. Sadler Cleavage of von Willebrand Factor Requires the Spacer Domain of the Metalloprotease ADAMTS13 J. Biol. Chem., August 8, 2003; 278(32): 30136 - 30141. [Abstract] [Full Text] [PDF] L. H. Caramuru, R. D. P. S. Soares, N. Y. Maeda, and A. A. Lopes Hypoxia and Altered Platelet Behavior Influence von Willebrand Factor Multimeric Composition in Secondary Pulmonary Hypertension Clinical and Applied Thrombosis/Hemostasis, July 1, 2003; 9(3): 251 - 258. [Abstract] [PDF] H.-M. Tsai Advances in the Pathogenesis, Diagnosis, and Treatment of Thrombotic Thrombocytopenic Purpura J. Am. Soc. Nephrol., April 1, 2003; 14(4): 1072 - 1081. [Abstract] [Full Text] [PDF] H.-M. Tsai Platelet Activation and the Formation of the Platelet Plug: Deficiency of ADAMTS13 Causes Thrombotic Thrombocytopenic Purpura Arterioscler Thromb Vasc Biol, March 1, 2003; 23(3): 388 - 396. [Abstract] [Full Text] [PDF] R. Schneppenheim, U. Budde, F. Oyen, D. Angerhaus, V. Aumann, E. Drewke, W. Hassenpflug, J. Haberle, K. Kentouche, E. Kohne, et al. von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP Blood, March 1, 2003; 101(5): 1845 - 1850. [Abstract] [Full Text] [PDF] H.-M. Tsai, B. Lammle, V. Bianchi, L. Alberio, M. Furlan, G. Remuzzi, M. Galbusera, and P. M. Mannucci Deficiency of ADAMTS13 and thrombotic thrombocytopenic purpura Blood, November 15, 2002; 100(10): 3839 - 3842. [Full Text] [PDF] B. Plaimauer, K. Zimmermann, D. Volkel, G. Antoine, R. Kerschbaumer, P. Jenab, M. Furlan, H. Gerritsen, B. Lammle, H. P. Schwarz, et al. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13) Blood, November 15, 2002; 100(10): 3626 - 3632. [Abstract] [Full Text] [PDF] J. E. Sadler A new name in thrombosis, ADAMTS13 PNAS, September 3, 2002; 99(18): 11552 - 11554. [Full Text] [PDF] K. Kokame, M. Matsumoto, K. Soejima, H. Yagi, H. Ishizashi, M. Funato, H. Tamai, M. Konno, K. Kamide, Y. Kawano, et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity PNAS, September 3, 2002; 99(18): 11902 - 11907. [Abstract] [Full Text] [PDF] J. L. Moake Thrombotic Microangiopathies N. Engl. J. Med., August 22, 2002; 347(8): 589 - 600. [Full Text] [PDF] G. Remuzzi, M. Galbusera, M. Noris, M. T. Canciani, E. Daina, E. Bresin, S. Contaretti, J. Caprioli, S. Gamba, P. Ruggenenti, et al. von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome Blood, July 18, 2002; 100(3): 778 - 785. [Abstract] [Full Text] [PDF] V. Bianchi, R. Robles, L. Alberio, M. Furlan, and B. Lammle Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura Blood, June 28, 2002; 100(2): 710 - 713. [Abstract] [Full Text] [PDF] J. N. George, J. E. Sadler, and B. Lammle Platelets: Thrombotic Thrombocytopenic Purpura Hematology, January 1, 2002; 2002(1): 315 - 334. [Abstract] [Full Text] P. M. Mannucci, M. T. Canciani, I. Forza, F. Lussana, A. Lattuada, and E. Rossi Changes in health and disease of the metalloprotease that cleaves von Willebrand factor Blood, November 1, 2001; 98(9): 2730 - 2735. [Abstract] [Full Text] [PDF] H. E. Gerritsen, R. Robles, B. Lammle, and M. Furlan Partial amino acid sequence of purified von Willebrand factor-cleaving protease Blood, September 15, 2001; 98(6): 1654 - 1661. [Abstract] [Full Text] [PDF] K. Fujikawa, H. Suzuki, B. McMullen, and D. Chung Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family Blood, September 15, 2001; 98(6): 1662 - 1666. [Abstract] [Full Text] [PDF] A. Veyradier, B. Obert, A. Houllier, D. Meyer, and J.-P. Girma Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases Blood, September 15, 2001; 98(6): 1765 - 1772. [Abstract] [Full Text] [PDF] J. C. Moore, C. P. M. Hayward, T. E. Warkentin, and J. G. Kelton Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders Blood, September 15, 2001; 98(6): 1842 - 1846. [Abstract] [Full Text] [PDF] K. R. McCrae, J. B. Bussel, P. M. Mannucci, G. Remuzzi, and D. B. Cines Platelets: An Update on Diagnosis and Management of Thrombocytopenic Disorders Hematology, January 1, 2001; 2001(1): 282 - 305. [Abstract] [Full Text] [PDF] N. Mistry, S. L. Cranmer, Y. Yuan, P. Mangin, S. M. Dopheide, I. Harper, S. Giuliano, D. E. Dunstan, F. Lanza, H. H. Salem, et al. Cytoskeletal regulation of the platelet glycoprotein Ib/V/IX-von Willebrand factor interaction Blood, November 15, 2000; 96(10): 3480 - 3489. [Abstract] [Full Text] [PDF] F. I. Pareti, A. Lattuada, C. Bressi, M. Zanobini, A. Sala, A. Steffan, and Z. M. Ruggeri Proteolysis of von Willebrand Factor and Shear Stress-Induced Platelet Aggregation in Patients With Aortic Valve Stenosis Circulation, September 12, 2000; 102(11): 1290 - 1295. [Abstract] [Full Text] [PDF] M. Furlan and B. Lammle Haemolytic-uraemic syndrome and thrombotic thrombocytopenic purpura--new insights into underlying biochemical mechanisms Nephrol. Dial. Transplant., August 1, 2000; 15(8): 1112 - 1114. [Full Text] [PDF] S L Allford and S J Machin Current understanding of the pathophysiology of thrombotic thrombocytopenic purpura J. Clin. Pathol., July 1, 2000; 53(7): 497 - 501. [Full Text] [PDF] H.-M. Tsai, L. Rice, R. Sarode, T. W. Chow, and J. L. Moake Antibody Inhibitors to von Willebrand Factor Metalloproteinase and Increased Binding of von Willebrand Factor to Platelets in Ticlopidine-Associated Thrombotic Thrombocytopenic Purpura Ann Intern Med, May 16, 2000; 132(10): 794 - 799. [Abstract] [Full Text] [PDF] A. Nandi, P. Estess, and M. H. Siegelman Hyaluronan Anchoring and Regulation on the Surface of Vascular Endothelial Cells Is Mediated through the Functionally Active Form of CD44 J. Biol. Chem., May 12, 2000; 275(20): 14939 - 14948. [Abstract] [Full Text] [PDF] P.L. Turecek, L. Pichler, W. Auer, G. Eder, K. Varadi, A. Mitterer, W. Mundt, U. Schlokat, F. Dorner, L.O. Drouet, et al. Evidence for Extracellular Processing of Pro-von Willebrand Factor After Infusion in Animals With and Without Severe von Willebrand Disease Blood, September 1, 1999; 94(5): 1637 - 1647. [Abstract] [Full Text] [PDF] L. Oleksowicz, N. Bhagwati, and M. DeLeon-Fernandez Deficient Activity of von Willebrand's Factor-cleaving Protease in Patients with Disseminated Malignancies Cancer Res., May 1, 1999; 59(9): 2244 - 2250. [Abstract] [Full Text] [PDF] M. Furlan, R. Robles, M. Galbusera, G. Remuzzi, P. A. Kyrle, B. Brenner, M. Krause, I. Scharrer, V. Aumann, U. Mittler, et al. von Willebrand Factor-Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic-Uremic Syndrome N. Engl. J. Med., November 26, 1998; 339(22): 1578 - 1584. [Abstract] [Full Text] [PDF] H.-M. Tsai and E. C.-Y. Lian Antibodies to von Willebrand Factor-Cleaving Protease in Acute Thrombotic Thrombocytopenic Purpura N. Engl. J. Med., November 26, 1998; 339(22): 1585 - 1594. [Abstract] [Full Text] [PDF] J. L. Moake Moschcowitz, Multimers, and Metalloprotease N. Engl. J. Med., November 26, 1998; 339(22): 1629 - 1631. [Full Text] M. Furlan, R. Robles, M. Solenthaler, and B. Lammle Acquired Deficiency of von Willebrand Factor-Cleaving Protease in a Patient With Thrombotic Thrombocytopenic Purpura Blood, April 15, 1998; 91(8): 2839 - 2846. [Abstract] [Full Text] [PDF] P. V. Jenkins, K. J. Pasi, and S. J. Perkins Molecular Modeling of Ligand and Mutation Sites of the Type A Domains of Human von Willebrand Factor and Their Relevance to von Willebrand's Disease Blood, March 15, 1998; 91(6): 2032 - 2044. [Abstract] [Full Text] [PDF] P. L. Turecek, H. Gritsch, L. Pichler, W. Auer, B. Fischer, A. Mitterer, W. Mundt, U. Schlokat, F. Dorner, H. J. M. Brinkman, et al. In Vivo Characterization of Recombinant von Willebrand Factor in Dogs With von Willebrand Disease Blood, November 1, 1997; 90(9): 3555 - 3567. [Abstract] [Full Text] [PDF] M. Furlan, R. Robles, M. Solenthaler, M. Wassmer, P. Sandoz, and B. Lammle Deficient Activity of von Willebrand Factor-Cleaving Protease in Chronic Relapsing Thrombotic Thrombocytopenic Purpura Blood, May 1, 1997; 89(9): 3097 - 3103. [Abstract] [Full Text] [PDF] H.-M. Tsai, I. I. Sussman, D. Ginsburg, H. Lankhof, J. J. Sixma, and R. L. Nagel Proteolytic Cleavage of Recombinant Type 2A von Willebrand Factor Mutants R834W and R834Q: Inhibition by Doxycycline and by Monoclonal Antibody VP-1 Blood, March 15, 1997; 89(6): 1954 - 1962. [Abstract] [Full Text] [PDF] X. Zheng, D. Chung, T. K. Takayama, E. M. Majerus, J. E. Sadler, and K. Fujikawa Structure of von Willebrand Factor-cleaving Protease (ADAMTS13), a Metalloprotease Involved in Thrombotic Thrombocytopenic Purpura J. Biol. Chem., October 26, 2001; 276(44): 41059 - 41063. [Abstract] [Full Text] [PDF]

	Copyright © 1996 by American Society of Hematology         Online ISSN: 1528-0020